Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
284.7 USD | +1.71% | 0.00% | -12.71% |
08/05 | UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating | MT |
08/05 | RBC Adjusts Price Target on Bio-Rad Laboratories to $414 From $420 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company appears to be poorly valued given its net asset value.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With an expected P/E ratio at 27.38 and 28.17 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.71% | 8.03B | - | ||
-4.83% | 182B | C+ | ||
+1.54% | 110B | C | ||
-3.22% | 68.11B | A | ||
+1.22% | 50.53B | B- | ||
+9.20% | 44.8B | B- | ||
+2.84% | 40.7B | B+ | ||
+21.07% | 32.25B | B | ||
+2.37% | 26.53B | A- | ||
+15.25% | 25.02B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BIO Stock
- BIO.B Stock
- Ratings Bio-Rad Laboratories, Inc.